Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vascular Normalization in Recurrent Glioblastoma Treated With Bevacizumab
NCT02076152Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2014
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of bevacizumab in glioblastoma (GBM) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Change in Tumor Blood Flow/Perfusion at Day 14 and Change in Tumor Hypoxic Volume at Day 14. Started Feb 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02076152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076152.